Literature DB >> 18096566

The impact of a false-positive MRI on the choice for mastectomy in BRCA mutation carriers is limited.

N Hoogerbrugge1, Y J L Kamm, P Bult, K M Landsbergen, E M H F Bongers, H G Brunner, H J Bonenkamp, J A de Hullu, M J L Ligtenberg, C Boetes.   

Abstract

PURPOSE: To assess the false-positive rate of breast cancer surveillance by magnetic resonance imaging (MRI) in BRCA mutation carriers and the impact of an abnormal mammography or breast MRI on the patients' decision for prophylactic mastectomy. PATIENTS AND METHODS: A total of 196 BRCA mutation carriers were included with a median follow-up of 2 years (range 1-9) with annual mammography and MRI. Preference for prophylactic mastectomy was registered at first surveillance after the mutation carriership was revealed.
RESULTS: In all, 41% (81 of 196) of the women had at least one positive MRI or mammography. Malignancy was detected in 17 women: 11 at surveillance, 4 at an intended prophylactic mastectomy and 2 had an interval cancer. Imaging by mammography and MRI had a sensitivity of 71% and a specificity of 90%. The probability that a positive MRI result is false positive was 83%. In the group with a prior preference for mastectomy with and without a false-positive imaging, prophylactic mastectomy was carried out in 89% and 66%, respectively (P = 0.06), in the group with prior preference for surveillance these percentages were 15% and 11%, respectively (P = 0.47).
CONCLUSION: Although the rate of false-positive MRI results is high, the impact on the choice for prophylactic mastectomy is limited and is determined by the woman's preference before the establishment of a BRCA mutation.

Entities:  

Mesh:

Year:  2007        PMID: 18096566     DOI: 10.1093/annonc/mdm537

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  6 in total

1.  Female BRCA mutation carriers with a preference for prophylactic mastectomy are more likely to participate an educational-support group and to proceed with the preferred intervention within 2 years.

Authors:  Karin M Landsbergen; Judith B Prins; Yvonne J L Kamm; Han G Brunner; Nicoline Hoogerbrugge
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

2.  Clinical utility gene card for: Hereditary diffuse gastric cancer (HDGC).

Authors:  Carla Oliveira; Raquel Seruca; Nicoline Hoogerbrugge; Marjolijn Ligtenberg; Fátima Carneiro
Journal:  Eur J Hum Genet       Date:  2013-02-27       Impact factor: 4.246

Review 3.  Evaluating the correlation between film mammography and MRI for screening women with increased breast cancer risk.

Authors:  Janie M Lee; Elkan F Halpern; Elizabeth A Rafferty; G Scott Gazelle
Journal:  Acad Radiol       Date:  2009-07-25       Impact factor: 3.173

Review 4.  Women's decision making about risk-reducing strategies in the context of hereditary breast and ovarian cancer: a systematic review.

Authors:  A Fuchsia Howard; Lynda G Balneaves; Joan L Bottorff
Journal:  J Genet Couns       Date:  2009-10-03       Impact factor: 2.537

5.  Predictive performance of BI-RADS magnetic resonance imaging descriptors in the context of suspicious (category 4) findings.

Authors:  João Ricardo Maltez de Almeida; André Boechat Gomes; Thomas Pitangueiras Barros; Paulo Eduardo Fahel; Mário de Seixas Rocha
Journal:  Radiol Bras       Date:  2016 May-Jun

Review 6.  Decision making for breast cancer prevention among women at elevated risk.

Authors:  Tasleem J Padamsee; Celia E Wills; Lisa D Yee; Electra D Paskett
Journal:  Breast Cancer Res       Date:  2017-03-24       Impact factor: 6.466

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.